WallStreetZenWallStreetZen

NASDAQ: SABS
Sab Biotherapeutics Inc Stock

$2.96+0.12 (+4.23%)
Updated Jun 24, 2024
SABS Price
$2.96
Fair Value Price
$6.32
Market Cap
$27.32M
52 Week Low
$2.36
52 Week High
$10.50
P/E
-0.44x
P/B
0.52x
P/S
16.12x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.60M
Earnings
-$39.87M
Gross Margin
100%
Operating Margin
-1,520.34%
Profit Margin
-1,531.8%
Debt to Equity
0.35
Operating Cash Flow
-$34M
Beta
0.63
Next Earnings
Jun 28, 2024
Ex-Dividend
N/A
Next Dividend
N/A

SABS Overview

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SABS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SABS ($2.96) is undervalued by 53.13% relative to our estimate of its Fair Value price of $6.32 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SABS ($2.96) is significantly undervalued by 53.13% relative to our estimate of its Fair Value price of $6.32 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
SABS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SABS due diligence checks available for Premium users.

Be the first to know about important SABS news, forecast changes, insider trades & much more!

SABS News

Valuation

SABS fair value

Fair Value of SABS stock based on Discounted Cash Flow (DCF)
Price
$2.96
Fair Value
$6.32
Undervalued by
53.13%
SABS ($2.96) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SABS ($2.96) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SABS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SABS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.44x
Industry
-6.96x
Market
30.03x

SABS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.52x
Industry
6.29x
SABS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SABS's financial health

Profit margin

Revenue
$944.6k
Net Income
-$5.0M
Profit Margin
-532.1%
SABS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SABS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$71.4M
Liabilities
$18.5M
Debt to equity
0.35
SABS's short-term assets ($46.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SABS's short-term assets ($46.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SABS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$10.8M
Investing
-$31.4M
Financing
-$394.4k
SABS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SABS vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
SABS$27.32M+4.23%-0.44x0.52x
RNXT$27.42M+4.09%-1.59x15.52x
PLUR$26.66M-0.44%-1.20x-74.90x
BCLI$26.63M+2.70%-1.19x-4.80x
COCP$26.55M-1.88%-1.58x1.18x

Sab Biotherapeutics Stock FAQ

What is Sab Biotherapeutics's quote symbol?

(NASDAQ: SABS) Sab Biotherapeutics trades on the NASDAQ under the ticker symbol SABS. Sab Biotherapeutics stock quotes can also be displayed as NASDAQ: SABS.

If you're new to stock investing, here's how to buy Sab Biotherapeutics stock.

What is the 52 week high and low for Sab Biotherapeutics (NASDAQ: SABS)?

(NASDAQ: SABS) Sab Biotherapeutics's 52-week high was $10.50, and its 52-week low was $2.36. It is currently -71.81% from its 52-week high and 25.42% from its 52-week low.

How much is Sab Biotherapeutics stock worth today?

(NASDAQ: SABS) Sab Biotherapeutics currently has 9,229,274 outstanding shares. With Sab Biotherapeutics stock trading at $2.96 per share, the total value of Sab Biotherapeutics stock (market capitalization) is $27.32M.

Sab Biotherapeutics stock was originally listed at a price of $104.00 in Jan 12, 2021. If you had invested in Sab Biotherapeutics stock at $104.00, your return over the last 3 years would have been -97.15%, for an annualized return of -69.47% (not including any dividends or dividend reinvestments).

How much is Sab Biotherapeutics's stock price per share?

(NASDAQ: SABS) Sab Biotherapeutics stock price per share is $2.96 today (as of Jun 24, 2024).

What is Sab Biotherapeutics's Market Cap?

(NASDAQ: SABS) Sab Biotherapeutics's market cap is $27.32M, as of Jun 25, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Sab Biotherapeutics's market cap is calculated by multiplying SABS's current stock price of $2.96 by SABS's total outstanding shares of 9,229,274.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.